Clinical Trials Logo

Clinical Trial Summary

The primary aim of this proposal is to present a novel, multimodal treatment strategy for increasing lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and aerobic exercise, targeted nutrient supplementation and pharmacologic intervention (melatonin).

We postulate that this strategy, together with the simultaneous management of symptoms that decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary objectives of improving clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days).


Clinical Trial Description

The Study Drugs:

Melatonin is a hormone that helps reduce inflammation and poor food absorption caused by cancer. It may also enhance the effects of ibuprofen.

Juven is a nutritional supplement that is designed to help build muscle and slow muscle breakdown.

Screening Tests:

Before you can start treatment on this study, you will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests will be performed:

- Blood (1 to 2 tablespoons) will be drawn for routine tests. This routine blood draw will include a pregnancy test for women who are able to have children. To be eligible to take part in this study, the pregnancy test must be negative.

- Additional blood (1 tablespoon) will be drawn to check your thyroid function and the levels of two B vitamins, if these have not been checked within the past 3 months.

- You will have a physical exam, including measurement of vital signs (blood pressure, heart rate, temperature, and breathing rate).

- You will have an electrocardiogram (ECG -- a test that measures the electrical activity of the heart).

- Your resting energy expenditure (energy used at rest) will be measured. with a calorie-measuring device. For this test, you will breathe in and out through your mouth for about 10 minutes to allow a calorie-measuring device to measure the oxygen your body uses, and from this it calculates how much energy your body uses at rest.

- You will be asked to fill out a questionnaire to rate your overall physical well-being, another questionnaire to rate your level of fatigue, and a third questionnaire to rate your experiences with 10 common symptoms in the past 24 hours (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, changes in appetite, sleep difficulty, and feeling of well being). In total, these questionnaires will take about 30 minutes to complete.

- You will complete a diary entry that lists all of the food and drinks you have had in the last 3 days. It should take about 10 minutes to complete.

- Your strength and stamina will be evaluated. This is measured by hand-grip and pinch strength tests that are done with both hands. These tests will see how hard you can grip a device with your hand and pinch the pads of another device called a pinch gauge. These tests will be done 3 times and your best scores will be used. Your strength and stamina will also be checked using the Get-Up-and-Go test and the 6-minute walk test. The Get-Up-and-Go test measures how long it takes to get up from sitting in a chair that has arms, walking 10 feet, turning around and walking back to the chair, and sitting down. The 6-minute walk test will measure the distance you can walk in 6 minutes on a 100-foot loop. You will walk 50 feet and then turn and walk back to the beginning. You will do this at a walking speed that feels comfortable and for as many times as you can in 6 minutes.

- Blood (1 to 2 tablespoons) will be drawn to check for markers of inflammation and nutrition status.

Study Drug Administration:

You will take one (1) 20mg capsule of melatonin every night. It can be taken with or without food. It should be taken with 8 ounces (1 cup) of water.

You will drink 90 calories of Juven, twice a day. Juven is a powder supplement that is mixed into 8 ounces of water. It is available in orange or grape flavors.

You will also be instructed to increase your daily calorie intake by at least 1,000 calories. To assist you in doing so, dietary advice will be given to you by a nurse or physician.

Exercise Training:

You will complete 2 exercise training sessions a week. The sessions will combine resistance and graded aerobic training.

Resistance training (with Thera-bands) is designed to increase the muscle-building effects of a hormone called testosterone. Thera-bands are rubber bands that you can hold or put around your feet to provide resistance to your muscles when you bend and flex your arms and legs.

You will be instructed in how to do 3 upper-body exercises (chest press, shoulder press, and arm pull down) and 3 lower-body exercises (leg press, leg extension, and leg flexion).

At your first visit, a physician will educate you to make sure that all exercises are done correctly.

Each repetition will take 12 seconds to complete (6 seconds to bend, then 6 seconds to straighten your arm or leg). When 6 repetitions are completed, the next week's set will be increased by 1 repetition.

Graded aerobic exercise is a walking/running program that may help you exercise longer.

Graded aerobic exercise involves walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate. There will be a 3-minute warm-up and a 3-minute cool-down before and after this exercise.

During your first visit, you will be shown how to monitor your heart rate and how to exercise at 70-80% of your maximum heart rate.

You will add 1 minute to your aerobic exercise at the start of each week.

You will receive your own customized aerobic and resistance exercise program based on your range of motion and risk for falls, which will be evaluated by the study staff.

If you experience chest pain, have a temperature over 100.4 °F, have a platelet count of lower than a certain level, have fresh bruises, or shortness of breath at rest, you will be advised to stop exercising until these are relieved.

Evaluations:

While on study, within 3 days of the days listed below, the following measurements will be monitored:

- Your lean body mass and weight will be checked at Days 15 and 29 using the Tanita TBF-310 body composition analyzer/scale. For measurements with the Tanita TBF 310, you will be asked to wear light clothes and to take off your shoes and socks when being weighed. You will stand on a special scale that will send an extremely low-energy, high-frequency electrical signal from one foot to your other foot. You should not be able to feel this at all.

- Your muscle mass (mid-arm muscle area) will be measured with a special tape.

- The thickness of a skin fold on your triceps (back of your upper arm) will be measured 3 times using skin fold calipers. Calipers are a gentle clamp-like device that is used on the outside of your body to measure skin thickness.

- At Day 29, your resting energy expenditure will be measured.

- On Days 15 and 29 of the study cycle, you will complete the same 3 questionnaires as at screening.

- Your caloric intake will be measured on Days 15 and 29.

- Your strength and stamina will be evaluated on Days 15 and 29.

- On Day 29, blood (1 to 2 tablespoons) will be drawn to check for markers of inflammation and nutrition.

- Blood (about 1 to 2 tablespoons) will be drawn for routine tests every 15 days while you are on-study. You will also have a fecal occult blood test at this time.

Length of Study:

You will be on study for 29 days (1 cycle).

This is an investigational study. Melatonin and Juven are commercially available nutritional supplements and are exempt from FDA approval. However, in patients with cancer and cachexia, the study treatment (resistance training, aerobic exercise, and the use of Juven, and melatonin) is considered experimental. At this time, it is only being used in research.

Up to 40 patients will be enrolled on this study. Up to 30 patients will be enrolled at M.D. Anderson, and 10 will be enrolled at the University of Alabama-Birmingham. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00625742
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Terminated
Phase N/A
Start date February 2008
Completion date June 2014

See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1